Approximately what percentage of type 2 patients do you have on SGLT-2 Inhibitors? 1. None 2. 5% 3. 10% 4. 15% 5. 20% or greater Follow the link to see how you and your colleagues compare!

Dr. Matthew Weir discusses the pros and cons of SGLT-2 drugs with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine at the University of Maryland. Dr. …

Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the impact of SGLT2 drugs on the possible improvement of kidney disease. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine …

At the the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir and Diabetes in Control Publisher Steve Freed discuss the impact of SGLT2 drugs in helpful as well as possibly harmful ways. They also look at the need for safety studies for kidney disease. Dr. Matthew Weir, MD is …

At the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed about how he detects kidney disease in an effort to catch and treat the condition in its early stages. Dr. Matthew Weir, MD is a professor of medicine and director of …

 When most of us think of a diabetes disaster, we think of severe hypoglycemia or the loss of a limb or failure of the kidneys; a devastating experience. But more than likely, the worst  disaster is the diagnosis of type one diabetes. How do you explain to a child that …

Since Team Novo Nordisk’s inaugural season in 2013, 30-year-old Romain Gioux has dreamed of racing as part of the world’s first all-diabetes pro cycling team. Diagnosed with type 1 diabetes at age 15, he raced as an amateur for a French-based Club, but this year serves as his professional debut.

Dr. Lance Sloan talks with Diabetes in Control Publisher Steve Freed at AACE 2016. In this Exclusive Interview, Dr. Sloan discusses SGLT-associated DKA.

Dr. Lance Sloan discusses his experience dealing with SGLT-associated DKA as an endocrinologist/nephrologist in clinical practice.

In this week's Homerun Slides, debunking the need for the early use of insulin.